Dabidol is the trade name of Dupliyuzumab Injection, and its role and efficacy is to treat moderate-to-severe atopic dermatitis over the age of 12 years, and the specific use of the drug should follow the doctor’s instructions. Duprizolizumab Injection is a targeted biologic agent, the drug’s function and efficacy is to control the intensity of the inflammatory response by inhibiting the transmission of immunomodulatory factors, and is currently indicated for the treatment of moderate-to-severe atopic dermatitis in adolescents and adults 12 years of age and older for whom the use of topical medications is not recommended or is not adequately controlled by topical medications. However, it should be noted that Dupliyuzumab Injection is contraindicated in people who are allergic to this drug, and there is a possibility of injection site reactions (e.g., redness, swelling, and hardness), headache, conjunctivitis, and other adverse reactions during the course of administration. Therefore, those who have the need to use this drug must be under the guidance of a doctor to standardize the use of drugs, do not blindly self-medication, in order to avoid adverse consequences.